Aqueous fluid sequencing shows promise for diagnosing intraocular lymphoma

aqueous-fluid-sequencing-shows-promise-for-diagnosing-intraocular-lymphoma.jpg

JAN 24, 2018

Ocular Pathology/Oncology, Uveitis


Primary intraocular lymphoma is a great masquerader and can be mistaken for uveitis, often delaying diagnosis. In this study, the authors explored whether metagenomic deep sequencing (MDS) of ocular fluid could replace biopsy as a diagnostic test for primary intraocular lymphoma.

Study design

Aqueous fluid samples from 2 patients—one with vitreal lymphoma and another with intraocular B-cell lymphoma—were sent for MDS. The high-throughput sequencing approach can detect pathogens as well as common and rare cancer mutations.

Outcomes 

The first patient was HIV positive. Sequencing detected the presence of Epstein-Barr virus (HHV-4/EBV) and human herpes virus 8 (HHV-8) RNA, both implicated in a type of HIV-related lymphoma. Vitrectomy in this case was suggestive of lymphoma.

In the second patient, a rare mutation was found in the MYD88 gene—an uncommon mutation associated with B-cell lymphoma. Vitrectomy, performed 1 year prior, was negative for lymphoma. Histopathology of the anterior chamber tap, however, showed lymphoma cells.

Limitations

These were only 2 cases in this proof-of-concept study. Further testing in infectious and noninfectious uveitis and lymphoma cases is necessary to assess whether diagnostic biopsy can be replaced by this technique.

Clinical significance

The findings presented here demonstrate that MDS can accurately detect pathogen-related causes of inflammation that drive intraocular lymphomas, as well as common and rare cancer-associated mutations, in just 20 to 50 µL of aqueous fluid.

If shown reliable, this technique could potentially improve detection rates and permit earlier management of intraocular lymphomas. Aqueous samples could easily be obtained in the clinic from patients with suspected lymphoma.

View Abstract British Journal of Ophthalmology, January 2018

https://www.aao.org/editors-choice/aqueous-fluid-sequencing-shows-promise-diagnosing-

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more